Integra LifeSciences (IART) Reports In-Line Q3 EPS, Revenues Miss; Raises FY18 Revenue Outlook, Maintains FY18 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Integra LifeSciences (IART) Reports In-Line Q3 EPS, Revenues Miss; Raises FY18 Revenue Outlook, Maintains FY18 EPS Guidance

Integra LifeSciences (IART) PT Lowered to $62 at JMP Securities

November 2, 2018 8:15 AM EDT

JMP Securities analyst, David Turkaly, lowered the price target on Integra LifeSciences (NASDAQ: IART) to $62.00 (from $66.00) while maintaining a Market Outperform rating following the company's 3Q report.

IART reported a solid uptick in organic growth in 3Q, which was mathematically... More

Integra LifeSciences (IART) PT Lowered to $58 at RBC Capital

November 1, 2018 6:41 AM EDT

RBC Capital analyst Glenn Novarro lowered the price target on Integra LifeSciences (NASDAQ: IART) to $58.00 (from $60.00) while maintaining a Sector Perform rating.

... More